Alexander Vorog

430 total citations
23 papers, 175 citations indexed

About

Alexander Vorog is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Alexander Vorog has authored 23 papers receiving a total of 175 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Hematology, 14 papers in Genetics and 9 papers in Molecular Biology. Recurrent topics in Alexander Vorog's work include Chronic Lymphocytic Leukemia Research (11 papers), Multiple Myeloma Research and Treatments (11 papers) and Chronic Myeloid Leukemia Treatments (11 papers). Alexander Vorog is often cited by papers focused on Chronic Lymphocytic Leukemia Research (11 papers), Multiple Myeloma Research and Treatments (11 papers) and Chronic Myeloid Leukemia Treatments (11 papers). Alexander Vorog collaborates with scholars based in United States, Italy and France. Alexander Vorog's co-authors include Meletios Α. Dimopoulos, Richard Labotka, Bingxia Wang, Xavier Leleu, Ivan Špıčka, María‐Victoria Mateos, Sara Bringhen, Hang Quach, Shinsuke Iida and Meral Beksaç and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Pharmacology & Therapeutics.

In The Last Decade

Alexander Vorog

20 papers receiving 173 citations

Peers

Alexander Vorog
Comparison fields: 5 of 39
  • Hematology 143
  • Molecular Biology 99
  • Oncology 83
  • Genetics 38
  • Public Health, Environmental and Occupational Health 25
Replace Luísa Viterbo with:
Luísa Viterbo Portugal
Vadim Doronin Russia
Atelda Romano Italy
Dorotea Fantl Argentina
Georgi Mihaylov Bulgaria
Ravi Vij United States
Christos Demosthenous Greece
Kamal Menghrajani United States
Rosane Bittencourt Brazil
Tomáš Szotkowski Czechia
Luísa Viterbo Portugal View profile →
Citations per field, relative to Alexander Vorog
Alexander Vorog · 1×
Citations per year, relative to Alexander Vorog
Alexander Vorog · 1×

Countries citing papers authored by Alexander Vorog

Since Specialization
Citations

This map shows the geographic impact of Alexander Vorog's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alexander Vorog with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alexander Vorog more than expected).

Fields of papers citing papers by Alexander Vorog

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alexander Vorog. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alexander Vorog. The network helps show where Alexander Vorog may publish in the future.

Co-authorship network of co-authors of Alexander Vorog

This figure shows the co-authorship network connecting the top 25 collaborators of Alexander Vorog. A scholar is included among the top collaborators of Alexander Vorog based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alexander Vorog. Alexander Vorog is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
# Work Indexed citations
1
Population Pharmacokinetic and Exposure–Response Analyses for Ponatinib in the Phase 3 PhALLCON Study
2025 ·Clinical and Translational Science ·Michael J. Hanley, Thomas R. Larson, Paul M. Diderichsen, (unknown), (unknown), (unknown), Bingxia Wang, Alexander Vorog, Neeraj Gupta
0
2
Ponatinib (PON) in patients (pts) with chronic-phase chronic myeloid leukemia (CP-CML) and the T315I mutation (mut): 4-year results from OPTIC.
2024 ·Journal of Clinical Oncology ·Michael W. Deininger, Jane Apperley, Christopher Arthur, Charles Chuah, Andreas Hochhaus, Hugues de Lavallade, Jeffrey H. Lipton, Elza Lomaia, James McCloskey, Lori J. Maness, Michael J. Mauro, Beatriz Moiraghi, Carolina Pavlovsky, Gianantonio Rosti, Philippe Rousselot, (unknown), Xiaowei Ren, Alexander Vorog, Hagop M. Kantarjian, Jörge E. Cortes
0
3
Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials
2024 ·Leukemia ·Elias Jabbour, Jane F. Apperley, Jörge E. Cortes, Delphine Réa, Michael W. Deininger, Elisabetta Abruzzese, Charles Chuah, Daniel J. DeAngelo, Andreas Hochhaus, Jeffrey H. Lipton, Michael J. Mauro, Franck E. Nicolini, Javier Pinilla‐Ibarz, Gianantonio Rosti, Philippe Rousselot, Neil P. Shah, Moshe Talpaz, Alexander Vorog, Xiaowei Ren, Hagop M. Kantarjian
15
4
Ponatinib Versus Imatinib in Patients with Newly Diagnosed Ph+ ALL: Subgroup Analysis of the Phase 3 Phallcon Study
2023 ·Blood ·Ibrahim Aldoss, Josep‐María Ribera, Hagop M. Kantarjian, Pau Montesinos, Jessica Leonard, David Gómez‐Almaguer, Maria R. Baer, Carlo Gambacorti‐Passerini, James McCloskey, Yosuke Minami, Cristina Papayannidis, Vanderson Rocha, Philippe Rousselot, Pankit Vachhani, Eunice S. Wang, Meliessa Hennessy, (unknown), Alexander Vorog, Bingxia Wang, Elias Jabbour
2
5
Response‐Based Dosing for Ponatinib: Model‐Based Analyses of the Dose‐Ranging OPTIC Study
2023 ·Clinical Pharmacology & Therapeutics ·Michael J. Hanley, Paul M. Diderichsen, Benjamin E. Rich, (unknown), (unknown), Alexander Vorog, Karthik Venkatakrishnan, Neeraj Gupta
6
6
Ixazomib Versus Placebo as Postinduction Maintenance Therapy in Newly Diagnosed Multiple Myeloma Patients: An Analysis by Age and Frailty Status of the TOURMALINE-MM4 Study
2023 ·Clinical Lymphoma Myeloma & Leukemia ·Sara Bringhen, Luděk Pour, Reuben Benjamin, Sebastian Grosicki, Chang‐Ki Min, Danielle Leão Cordeiro de Farias, Alexander Vorog, Richard Labotka, Bingxia Wang, (unknown), Lauren E. Cain, Sudhakar Manne, S. Vincent Rajkumar, Meletios Α. Dimopoulos
2
7
A pooled analysis of outcomes according to cytogenetic abnormalities in patients receiving ixazomib- vs placebo-based therapy for multiple myeloma
2023 ·Blood Cancer Journal ·Wee Joo Chng, Sagar Lonial, Gareth J. Morgan, Shinsuke Iida, Philippe Moreau, Shaji Kumar, Philip Twumasi‐Ankrah, (unknown), Ajeeta B. Dash, Alexander Vorog, Xiaoquan Zhang, Kaveri Suryanarayan, Richard Labotka, Meletios Α. Dimopoulos, S. Vincent Rajkumar
1
8
MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials
2022 ·Blood ·Bruno Paiva, Irene Manrique, Meletios Α. Dimopoulos, Francesca Gay, Chang‐Ki Min, Sonja Zweegman, Ivan Špıčka, Raphael Teipel, María‐Victoria Mateos, Nicola Giuliani, Michèle Cavo, (unknown), Weijun Fu, Kaveri Suryanarayan, Alexander Vorog, Cong Li, Bingxia Wang, Jose Estevam, Richard Labotka, Ajeeta B. Dash
25
9
Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial
2022 ·Blood Cancer Journal ·Meletios Α. Dimopoulos, Fredrik Schjesvold, Vadim Doronin, (unknown), Hang Quach, Xavier Leleu, (unknown), Karthik Ramasamy, Alessandra Pompa, Mark‐David Levin, Cindy Lee, (unknown), Roland Fenk, Hélène Demarquette, Hamdi Sati, Alexander Vorog, Richard Labotka, (unknown), Mohamed Darif, Shaji Kumar
15
10
P-052: Measurable residual disease (MRD) dynamics during maintenance with ixazomib vs placebo in 1280 newly diagnosed multiple myeloma (NDMM) patients: a pooled analysis of the TOURMALINE-MM3 and -MM4 trials
2022 ·Clinical Lymphoma Myeloma & Leukemia ·Bruno Paiva, Irene Manrique, Meletios Α. Dimopoulos, Francesca Gay, Chang‐Ki Min, Sonja Zweegman, Ivan Špıčka, Raphael Teipel, María‐Victoria Mateos, Nicola Giuliani, Michèle Cavo, (unknown), (unknown), Kaveri Suryanarayan, Alexander Vorog, Cong Li, Bingxia Wang, Jose Estevam, Richard Labotka, Ajeeta B. Dash
0
11
CML-047 Post Hoc Analysis of Responses to Ponatinib in Patients With Chronic-Phase Chronic Myeloid Leukemia (CP-CML) by Baseline BCR::ABL1 Level and Baseline Mutation Status in the OPTIC Trial
2022 ·Clinical Lymphoma Myeloma & Leukemia ·Michael Deininger, Jane Apperley, Christopher Arthur, Charles Chuah, Andreas Hochhaus, Hugues de Lavallade, Jeffrey H. Lipton, Elza Lomaia, James A. McCloskey, Lori J. Maness, Michael J. Mauro, (unknown), Carolina Pavlovsky, Gianantonio Rosti, Philippe Rousselot, (unknown), Xiaowei Ren, Alexander Vorog, Jörge E. Cortes
1
12
Interim Analyses of Overall Survival (OS) from the TOURMALINE MM3 & MM4 Studies of Ixazomib Maintenance Following Primary Therapy in Multiple Myeloma (MM)
2021 ·Blood ·Meletios Α. Dimopoulos, S. Vincent Rajkumar, Sagar Lonial, Wee Joo Chng, Shinsuke Iida, María‐Victoria Mateos, Gareth J. Morgan, Arun Kumar, Kaveri Suryanarayan, Alexander Vorog, (unknown), Richard Labotka
2
13
Oral ixazomib-dexamethasone versus oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma (MM) patients: A global, multicenter, randomized, open-label, phase 2 trial.
2021 ·Journal of Clinical Oncology ·Meletios Α. Dimopoulos, Fredrik Schjesvold, Vadim Doronin, (unknown), Hang Quach, Xavier Leleu, (unknown), Karthik Ramasamy, Alessandra Pompa, Mark‐David Levin, Cindy Lee, Ulf‐Henrik Mellqvist, Roland Fenk, Hamdi Sati, Alexander Vorog, Richard Labotka, (unknown), Mohamed Darif, Shaji Kumar
1
14
Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial
2020 ·Journal of Clinical Oncology ·Meletios Α. Dimopoulos, Ivan Špıčka, Hang Quach, Albert Oriol, Roman Hájek, Mamta Garg, Meral Beksaç, Sara Bringhen, Eirini Katodritou, Wee Joo Chng, Xavier Leleu, Shinsuke Iida, María‐Victoria Mateos, Gareth J. Morgan, Alexander Vorog, Richard Labotka, Bingxia Wang, Antonio Palumbo, Sagar Lonial, (unknown)
53
15
Prognostic Importance of Measurable Residual Disease (MRD) Kinetics and Progression-Free Survival (PFS) Benefit in MRD+ Patients (Pts) with Ixazomib Vs Placebo As Post-Induction Maintenance Therapy: Results from the Multicenter, Double-Blind, Phase 3 TOURMALINE-MM4 Trial in Non-Transplant Newly Diagnosed Multiple Myeloma (NDMM) Pts
2020 ·Blood ·Bruno Paiva, Irene Manrique, Nicola Giuliani, Michèle Cavo, Christine Rojas, Weijun Fu, María‐Victoria Mateos, Meletios Α. Dimopoulos, Alexander Vorog, Cong Li, Bingxia Wang, Richard Labotka, Ajeeta B. Dash
1
16
Ixazomib vs placebo maintenance for newly diagnosed multiple myeloma (NDMM) patients not undergoing autologous stem cell transplant (ASCT): The phase III TOURMALINE-MM4 trial.
2020 ·Journal of Clinical Oncology ·Meletios Α. Dimopoulos, Ivan Špıčka, Hang Quach, Albert Oriol, Roman Hájek, Mamta Garg, Meral Beksaç, Sara Bringhen, Eirini Katodritou, Wee Joo Chng, Xavier Leleu, Shinsuke Iida, María‐Victoria Mateos, Gareth J. Morgan, Alexander Vorog, Richard Labotka, Bingxia Wang, Antonio Palumbo, Sagar Lonial
5
17
Progression-Free Survival (PFS) Benefit Demonstrated and Quality of Life (QoL) Maintained across Age and Frailty Subgroups with the Oral Proteasome Inhibitor (PI) Ixazomib Vs Placebo As Post-Induction Maintenance Therapy in Non-Transplant Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Analysis of the TOURMALINE-MM4 Phase 3 Trial
2020 ·Blood ·Sara Bringhen, Luděk Pour, (unknown), Sebastian Grosicki, Chang‐Ki Min, Danielle Leão Cordeiro de Farias, Alexander Vorog, Richard Labotka, Bingxia Wang, (unknown), Lauren E. Cain, Sudhakar Manne, S. Vincent Rajkumar, Meletios Α. Dimopoulos
7
18
A Phase 1 First-in-Human Study of the Anti-CD38 Dimeric Fusion Protein TAK-169 for the Treatment of Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM) Who Are Proteasome Inhibitor (PI)- and Immunomodulatory Drug (IMiD)-Refractory, Including Pts Relapsed/Refractory (R/R) or Naïve to Daratumumab (dara)
2019 ·Blood ·Shaji Kumar, Robert F. Cornell, Ola Landgren, Sikander Ailawadhi, Jack P. Higgins, Erin K. Willert, Roger J. Waltzman, Jianchang Lin, Yuhong Zhang, Anya Lublinsky, Ajeeta B. Dash, Michael J. Hanley, (unknown), (unknown), (unknown), Richard Labotka, John Newcomb, Alexander Vorog
7
19
Association of Liver Iron Concentration Levels with Myocardial T2* Responses in Transfusion-Dependent Thalassemia Major Patients Treated with Deferasirox and Deferoxamine- Extension of Cordelia Study
2015 ·Blood ·Dudley J. Pennell, John B. Porter, Antonio Piga, Jackie Han, Alexander Vorog, Yeşim Aydınok
1
20
Human immunodeficiency virus infection and chronic myeloid leukemia
2012 ·Leukemia Research ·Moosa Patel, (unknown), (unknown), (unknown), Alexander Vorog, (unknown), Alan Karstaedt, (unknown)
14

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Luísa Viterbo Breakdown of academic impact, for papers by Vadim Doronin Breakdown of academic impact, for papers by Atelda Romano Breakdown of academic impact, for papers by Dorotea Fantl Breakdown of academic impact, for papers by Georgi Mihaylov Breakdown of academic impact, for papers by Ravi Vij Breakdown of academic impact, for papers by Christos Demosthenous Breakdown of academic impact, for papers by Kamal Menghrajani Breakdown of academic impact, for papers by Rosane Bittencourt Breakdown of academic impact, for papers by Tomáš Szotkowski
Rankless by CCL
2026